Terlipressin intravenous - Orphan Therapeutics

Drug Profile

Terlipressin intravenous - Orphan Therapeutics

Alternative Names: Lucassin

Latest Information Update: 22 Nov 2016

Price : $50

At a glance

  • Originator Orphan Therapeutics LLC
  • Developer Mallinckrodt plc; Orphan Therapeutics
  • Class Antidiuretics; Antihaemorrhagics; Vasoconstrictors; Vasopressins
  • Mechanism of Action Vasopressin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatorenal syndrome
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Hepatorenal syndrome
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hepatorenal syndrome

Most Recent Events

  • 16 Nov 2016 Efficacy data from a post-hoc analysis of two clinical trials released by Mallinckrodt
  • 26 Jul 2016 Terlipressin is still in registered phase for Hepatorenal syndrome in France, Ireland, South Korea, Spain, Mexico, Taiwan, India and Portugal (IV)
  • 26 Jul 2016 Mallinckrodt initiates enrolment in the phase III CONFIRM trial for Hepatorenal syndrome in USA (NCT02770716)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top